TCT 730: Leaflet Modification Without General Anesthesia or TEE in High-Risk TAVR: A Conscious Sedation Approach Using BASILICA and UNICORN Receive the the latest news, research, and presentations ...

In this retrospective cohort study designed to assess long-term safety outcomes of drug-coated devices (DCDs) versus ...

What if you'd invested in Boston Scientific (BSX) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today? With that ...

LAS VEGAS, Nov. 4, 2025 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, ...

Acotec Scientific Holdings Limited (($DE:7W3)) announced an update on their ongoing clinical study. Study Overview: Acotec Scientific Holdings ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI).

Dr. Mehran is a co-Principal Investigator of the breakthrough "SELUTION4ISR Trial," with results presented at Transcatheter Cardiovascular Therapeutics 2025. A new drug-eluting balloon can perform ...

A state appeals court on Wednesday ruled in favor of a Frederick County hot-air balloon company in a case brought by a Union Bridge couple who alleged an invasion of privacy, among other things, as a ...

New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates found that utilizing a strategy of sirolimus-eluting balloons with bailout ...